Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-08-12

Clinical Trial Update: Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B

View source ↗

Summary

Post-marketing surveillance trial completed to observe safety and efficacy of BeneFIX in patients with Hemophilia B. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia B | Status: COMPLETED | Results posted: 2013-08-12